North Star Asset Management Inc. increased its stake in Pfizer Inc. (NYSE:PFE) by 1.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 246,971 shares of the biopharmaceutical company’s stock after purchasing an additional 3,691 shares during the quarter. North Star Asset Management Inc.’s holdings in Pfizer were worth $8,449,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Shine Investment Advisory Services Inc. bought a new position in Pfizer in the second quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware bought a new position in Pfizer in the second quarter worth approximately $103,000. D. Scott Neal Inc. raised its position in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares during the period. Herndon Capital Management LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at $120,000. Finally, Private Vista LLC raised its position in shares of Pfizer by 2,277.3% during the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 190,933 shares during the period. Institutional investors own 69.74% of the company’s stock.
PFE has been the topic of several recent analyst reports. Jefferies Group set a $37.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research report on Monday, September 18th. Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a research note on Wednesday, December 27th. Deutsche Bank set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Goldman Sachs Group set a $36.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, November 1st. Finally, BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Friday, December 15th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $38.83.
In related news, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the transaction, the insider now owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 29,450 shares of company stock valued at $1,065,220. Company insiders own 0.06% of the company’s stock.
Shares of Pfizer Inc. (NYSE PFE) opened at $36.54 on Friday. Pfizer Inc. has a twelve month low of $30.90 and a twelve month high of $37.35. The firm has a market cap of $217,800.00, a PE ratio of 22.42, a P/E/G ratio of 2.44 and a beta of 1.01. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. During the same quarter in the previous year, the business posted $0.61 EPS. The company’s quarterly revenue was up .9% compared to the same quarter last year. equities analysts forecast that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a $0.34 dividend. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 annualized dividend and a dividend yield of 3.72%. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is currently 78.53%.
Pfizer announced that its board has authorized a stock repurchase program on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.